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Menopausal estrogens are now being prescribed not only for symptom relief, but also to
prevent the long-term sequelae ofestrogen deficiency, namelyosteoporosis and atherosclerotic
disease. The well-established association between endometrial cancer and estrogen replace-
ment therapy (ERT) has become less of a clinical concern due to the recognition of the
protective effect ofprogestogens in this setting. A small literature has emerged suggesting that
extending ERT to the woman with a history of endometrial carcinoma imposes no increased
risk of recurrence and may improve survival. Candidates for ERT should be women with a
better prognostic profilewith reference to their cancer.
The relationship between ERT and breast cancer remains a topic of intense debate and
investigation. Overall, the current literature finds no significant increase in risk among healthy
women without a family history ofbreast cancer. There are no guidelines with reference to the
woman with a history of breast cancer and the use of ERT. The most prudent approach with
this population is to consider alternative treatments until more is known.
BACKGROUND
It has been over 15 years since the first retrospective, case-control studies were
published which causally linked estrogen replacement therapy (ERT) with the
development of endometrial cancer [1-3]. The ensuing publicity led to a significant
decline in the use ofsuch preparations. Fortunately, over the last decade, prodigious
research into the menopause has elucidated much about the biology of the female
climacteric and its clinical consequences. As the human life span lengthens, the full
effect ofovarian hormonal decline is onlybeginning to be appreciated.
The available literature is replete with data supporting the use of menopausal
estrogens. Reliefofthe menopausal syndrome (i.e., vasomotor instability, genitouri-
nary atrophy, and so on) is awell-established benefit ofERT [4]. Moreover, the best
anti-resorptive protocol for the treatment of post-menopausal osteoporosis is ERT
[5-10]. The beneficial effect of such treatment is often unappreciated unless one
considers the following: (1) 25 percent of women over 60 years of age have
radiographic evidence of vertebral crush fractures; (2) women who suffer hip
fractures have a mortality rate 20 times that expected for age; (3) during the 1980s
the cost for proximal femur fractures in the U.S. exceeded $3 billion annually [11].
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Of even more staggering clinical significance is the burgeoning literature suggest-
ing that ERT may be protective against coronary heart disease (CHD) [12-29].
Amongthese studies with considerablevariability in design, population, definition of
estrogen use, and end-point, the vast majority (greater than 80 percent) demon-
strated a reduction in the risk of CHD among estrogen users of 30 to 50 percent or
greater. Indeed, this beneficial effect is biologically plausible, inasmuch as estrogens
have a marked anti-atherogenic effect onlipids andlipoproteins and do not adversely
affect other risk factors for CHD, i.e., obesity, blood pressure, clotting factors.
The complex clinical picture which emerges in the older post-menopausal women
combines menopausal changes with age-related disease processes. Is longevity-as
well as quality of life-enhanced by ERT? Several investigators have looked at
estrogen use and overall mortality [22,24,25,26,28,30,31,32]. Consistently estrogen
use was associated with a substantial reduction in mortality, which generally re-
flected reduced deaths from acute and chronic sequelae ofocclusive atherosclerotic
vascular diseases. In a recent report by Henderson et al., 8,881 post-menopausal
residents of a retirement community in southern California were followed for 7½/2
years: not only was estrogen use associated with protection from atherosclerotic
disease, but mortality from cancer was also reduced, although not to a statistically
significant degree [32].
Recognition of the benefits just outlined has resulted in a 43 percent increase in
estrogen prescriptions dispensed in the United States, from 14 million in 1980 to 20
million in 1986. As women become more aggressive consumers of medical care, the
interest in menopausal estrogens has increased dramatically. The lay press has
consistently "followed" the medical literature regarding ERT and further intensified
public debate. "Absolute contraindications" for the use ofestrogens, a listwhich was
historically of mammoth proportion, now include: (1) pregnancy; (2) history of
estrogen-sensitive neoplasia; (3) active hepatic disease; (4) active thromboembolic
disease; (5) undiagnosed genital bleeding. This review will focus on our current
knowledge regarding the risks associated with ERT in a high-risk population-
women with a history ofendometrial or breast carcinoma. Many ofthese women are
suffering from severe vasomotor symptoms and the sequelae of genitourinary atro-
phy. Moreover, among those with a good prognosis for survival, the long-term
consequences of estrogen deprivation are as significant as those among women
without a cancer history.
ENDOMETRIAL CANCER
Estrogens as Trophic Hormones
As early as 1923, Allen and Doisy characterized estrogens as primary trophic sex
hormones [33]. There is currently abundant biochemical and morphological informa-
tion available which clarifies the relationship between sex steroids and the endome-
trium.
Estrogen diffuses acrosscell membranes and isbound inthe cytoplasm to aspecific
receptor protein [34,35]. As discussed by Peterson et al., estrogenic activity at the
cellular level is dependent upon the relative affinity of the hormone for estrogen-
receptor protein [36]. Estradiol appears to be the most potent stimulator of cell
biosynthesis, although stimulatory effects are noted with estrone. The most impor-
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TABLE 1
Risk Estimates from Case-Control Studies ofEstrogen Replacement
Therapy and Endometrial Cancer
Study Relative Risksa
Author Year Ever Users Long-Term Users
Smith 1975 4.5
Ziel 1975 7.6 13.9
Mack 1976 5.6 8.8
Gray 1977 3.1 11.6
McDonald 1977 2.0 7.9
Wigle 1978 2.2 5.2
Horwitz 1978 12.0
Hoogerland 1978 2.2 6.7
Antunes 1979 6.0 15.0
Weiss 1979 7.5 8.2
Hulka 1980 4.2
Shapiro 1980 3.9 6.0
Jelovsek 1980 2.4 4.8
Spengler 1981 3.2 8.6
Stavraky 1981 4.2 14.4
Kelsey 1982 8.2
LaVecchia 1982 2.7
Henderson 1983 1.4 3.1
'Risk relative to never-users
Reproduced with permission from [36]
tant direct clinical consequence of estrogen stimulation of cell biosynthesis/
proliferation is the potential for endometrial hyperplasia.
The risk of developing endometrial hyperplasia increases with increasing dosages
of estrogen. Moreover, hyperplasia can progress to adenomatous hyperplasia and
then atypical adenomatous hyperplasia. The latter has been reported to be a
pre-malignant lesion [37,38]. Nearly 50 percent of 115 women with hyperplasia
studied by Wentz developed adenocarcinoma during a two- to eight-year follow-up
[39]. Of the 75 women with adenomatous hyperplasia, 76.7 percent developed
adenocarcinoma. Of 22 women who had atypical adenomatous hyperplasia, 81.8
percent developed cancer.
MenopausalEstrogens andEndometrial Carcinoma
Endometrial cancer rates did not change significantly in the U.S. from the 1930s
until about 1970 [40]. Several epidemiologic studies have demonstrated, however,
that as the saleofnon-contraceptive estrogensincreased intheearly 1970s, so didthe
incidence ofendometrial carcinoma [41-45]. Moreover, in three ofthese reports the
conversewas alsoreported: assalesdeclined, fewercasesofendometrial cancerwere
identified [41,44,45].
Needless to say, these observed trends do not verify a causal relationship.
Case-control studies abound on this topic, however, and the results have supported
similar conclusions (Table 1). The majority were conducted in the U.S. and em-
ployed unopposed conjugated estrogens as the estrogen treatment schedule. Estro-
gen use (compared tonon-use) was associatedwith a twofold tofifteenfold increased
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risk ofdeveloping endometrial cancer. Higher riskwas observed with higher dosages
and longer duration oftreatment [1-3,46-61].
The value of case-control studies in measuring the association between exposure
and disease has been questioned due to the inherent biases found in these designs
[36]. Fortunately, Hulka et al. [53] and Shapiro et al. [54] selected cases and controls
in a fashion designed to limit selection bias. They found that selection bias does not
entirely account for the observed association between estrogen use and endometrial
cancer. Moreover, these authors also controlled for confounding (i.e., factors associ-
ated with both estrogen administration and endometrial cancer are distributed
equally between cases and controls) variables. In addition, most ofthe studies listed
in Table 1 included large enough sample sizes to make it unlikely that the increased
relative-risk estimates are secondary to chance.
Several cohort studies have evaluated the effect ofnon-contraceptive estrogen use
on the risk of developing endometrial cancer [12,37,44,61]. Although most of these
studies include a relatively small number of women with endometrial cancer, they
generally concurwith thefindings ofthe case-control studies.
What emerges from the cohort studies is the effect ofprogestogens in modulating
the growth-promoting effect of estrogen on the endometrium. For example, Gam-
brell et al. found that estrogen-progestogen users had an incidence of endometrial
cancer of 56 per 100,000 women-years, much lower than the incidence of 359 per
100,000women-years amongestrogen users alone and even lessthan thatobserved in
women not receiving any ERT (248 per 100,000 women-years) [37]. The biologic
plausibility of these clinical observations is substantiated by extensive work showing
that progestogens reduce the number of available estrogen receptors and promote
the conversion of estradiol to the weaker steroid, estrone, through induction of
17-beta estradiol dehydrogenase [62,63]. The addition of progestogens to the treat-
ment schedules ofpost-menopausalwomen on estrogen lowers the nuclearestradiol-
to-estrone ratio relative to that observed in women treatedwith unopposed estrogen
[64]. Moreover, Nordqvist has shown that endometrial cells exposed to progesterone
in vitro have reduced synthesis of DNA and RNA [65]. Finally, Whitehead and
colleagues have shown that in vivo stimulation ofpost-menopausal endometrium by
estrogens cannot only be modified by progestogen treatment but that the progesto-
gen effect is dependent upon dose and duration [63].
These observations form the framework upon which current clinical practice is
based regarding the use of progestogens with menopausal ERT. This topic has
recentlybeen extensively reviewed by Whitehead et al. [66].
Substantial evidence suggests that women with adenocarcinoma of the endome-
trium associated with estrogen use have a considerably better long-term prognosis
compared to non-users with this malignancy. The data which support this observa-
tion come from separate areas ofinvestigation. To begin with, numerous published
reports indicate that endometrial cancer in a setting of estrogen use is generally of
low stage, low grade, and demonstrates less myometrial invasion [3,47,51,53,59,67].
In addition, several investigators have demonstrated that women with endometrial
cancer who have used menopausal estrogens prior to their diagnosis have a survival
advantage from all causes ofdeath [67-70]. As notedby Schwartzbaum et al. in their
recent investigation, the survival advantage of estrogen use is not solely due to
selection bias (i.e., women selected to use estrogen are healthier and would have
livedlongerregardless ofestrogenconsumption) [70]. In this report, aswell as oneby
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Collins et al., the risk of death from all causes was two to three times greater for
women who did not use estrogen (Fig. 1) [69,70]. In contrast, Robboy and Bradley
[71] and Smith et al. [72] found that when histologic grade was added to the model,
the survival advantage for estrogen users was nullified. As addressed by Schwartz-
baum et al., however, the studies by Robboy and Bradley and Smith dealt with a
small number of deaths, and therefore these reports may not have the statistical
power to detect survival advantage among estrogen users after histological grade was
controlled. Moreover, an argument for not adjusting for thisvariable is that estrogen
is responsible forthe development ofa lessaggressive cancer. Ifearlystage and lower
grade are the results of a biologic process leading to a more curable disease, then
stage andgrade are interveningvariables andshouldnotbe controlled [70]. Schwartz-
baum et al. also point out that estrogen use might cause a women to be examined
earlier and therefore have her neoplasia diagnosed at a more treatable point [70].
This possibility would make stage and grade confounding variables to be controlled
for in the design model. These authors exercise extreme caution in their study and
control for stage and grade. Regardless, theyfound a survival advantage for estrogen
userswhich becomes more pronounced as estrogen use is extended beyond 3.5 years.
Estrogen Replacement Therapy (ERT) andEndometrial CancerRecurrence
Compared to the voluminous literature just summarized, the available "data" on
the use of ERT in women with previous endometrial carcinoma stands in sharp
contrast (Table 2). The therapeutic dictum that estrogen is contraindicated in this
population is not based on any investigative work regarding the biological effects of
ERT on endometrial carcinoma. Indeed, the initial clinical data suggest that there is
no increase in recurrence ormortality. Treatment ofthispatient population exempli-
fies the complexities often faced in clinical practice regarding risk:benefit ratio
considerations.
Table 2 summarizes published reports to datewhich have attempted to investigate
the relationship between ERT and endometrial cancer recurrence. These observa-
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tional studies lend credence to the consideration of ERT in an individualized setting
[73-76].
Creasman et al. studied 221 patients with stage I adenocarcinoma of the endome-
trium at the Duke University Medical Center [75]. Forty-seven women were placed
on ERT in a non-randomized fashion. The entire group was followed for at least two
years after cancertherapy or until death. Seventy-two percent ofthe ERT users were
prescribed vaginal conjugated estrogens (0.625 or 1.25 mg every day for one month
and then three times per week thereafter). The patients in this group received at
least three months of estrogen and up to 84 months, with a median of 26 months.
ERTwas initiated 0 to 81 months after definitive cancer therapy (median interval, 18
months).
There was no statistically significant difference in the distribution of prognostic
factors between the two groups: i.e., stage, grade, depth of invasion, nodal metasta-
sis, peritoneal cytology, hormone receptor status. The authors note, however, that
the "trends for several factors were toward more favorable disease status in the
estrogen subgroup" [75].
There were 26 recurrences among the 174 (14.9 percent) non-users of estrogen
whereas there was only one (2.1 percent) recurrence in the user population. Sixteen
of the 27 recurrences among the non-estrogen users died from their disease. Ten
patients in this group died of "intercurrent disease": no further elaboration is
provided by the authors. The single patient from the estrogen-treated group who
succumbed from her disease recurred at 22 months. Her exposure to estrogen was
brief (three months), approximately 18 months before her recurrence.
The authors of this report wereclearlycognizant of the inherent weakness of their
retrospective analysis compared to a prospective, randomized trial. Selection bias
may well have influenced their findings; i.e., the length of time from primary
treatment of the cancer to the initiation of ERT (median, 18 months) may have
eliminated some women who would develop a recurrence. Given these methodologi-
cal flaws, the authors employed statistical analysis to adjust for differences in the two
groups based on prognostic factors associated with disease course and survival.
In summary, although this report deals with stage I disease only and may reflect
results primarily in a population treated with estrogen after a specific disease-free
interval from cancer therapy, their results have far-reaching implications. The
significance, if any, of the predominant type of estrogen vehicle (vaginal cream)
employed is unknown.
Recently, Lee et al. followed 144 patients with stage I disease over an 11-year
period atMadiganArmyMedical Center and BrookArmy Medical Center [76]. Only
patients considered at low risk for recurrence based on tumor grade (grades 1 or 2),
myometrial invasion(less than one-halfmyometrial invasion), and metastatic disease
(absent) were offered treatment. Forty-four selected patients were placed on oral
estrogen therapy and followed for a minimum of two years. Twenty-five of these
patients began ERT "within the first postoperative year": no further details are
available in terms of the time from surgery to initiation of estrogen. Fifteen were
prescribed "a progestin" at some time during the observation; scheduling details
(i.e., sequential versus continuous use) were not provided.
Among the estrogen users, there were no recurrences. This finding contrasts with
the eight recurrences (8 percent) which occurred among the 99 non-estrogen users.
What isquitenoteworthy, however, is that the vast majority ofthe recurrences in this
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group (seven out of eight) was found in a subgroup of 37 women with high-risk
factors. Indeed, no significant difference was found between estrogen users and
low-risk non-users. Eight deaths occurred from other diseases among the non-users:
five ofthose were from myocardial infarction.
In summary, this report is in agreement with the previously discussed study of
Creasman et al. [75]. Women with a low-risk profile for recurrence of endometrial
carcinoma appear not to incur any increased risk from the addition of menopausal
estrogens. This study takes note of the predominant non-malignant cause of death
among non-users-myocardial infarction. Despite the very small number ofpatients
in this subgroup, the clinical implications are overwhelmingly apparent. Twenty-five
patients in the ERT group were treated less than one year after definitive cancer
treatment. Again, this number is too small to make broad conclusions, but the
suggestion that low-risk women may be early candidates for estrogen is inherent. In
addition, these investigators studied women on oral therapy, which reflects the more
general clinical practice.
Two other purely observational reports have also been published [73,74]. Baker
followed 31 women with "an excellent prognosis for cure" who chose ERT due to
menopausal symptoms and concerns about osteoporosis risks [73]. Ten of these
women with "more advanced" disease, status post-surgery and radiation therapy,
waited an average of41/2 years before commencing ERT. The remainder (21) began
estrogen within 1.8 years of surgical treatment. The majority (23 out of 31) were
prescribed oral estrogen. There have not been any recurrences among the estrogen
users.
Between 1975 and 1988, Bryant followed 20 women who were treated with oral
estrogen after definitive surgery for endometrial carcinoma [74]. Conjugated equine
estrogen, 0.625 mg, every daywas begun 18 to 24 months post-operatively. One to 11
years after initiating ERT, cancer recurrence has not occurred. Of note is the fact
that, within this small population, sevenwomen had grade II lesions and fourwomen
had invasion involving greater than one-third ofthe myometrium.
Conclusion
The evidence is quite clear that the benefits of estrogen use in terms of the
prevention of osteoporosis and cardiovascular disease far outweigh the risk of
endometrial carcinoma. The question raised by the previously discussed reports is
whether ERT is contraindicated in thewomanwho hasbeen treated for endometrial
cancer. Clearly, the definitive study has not been done, i.e., a larger, randomized
prospective design. The clinical data to date, however, appear to argue strongly
against a pervasive clinical practice of eliminating these patients from treatment
consideration.
Therapy needs to be individualized, based on the patient's needs, her history as
well as her course on ERT. The best candidate appears to be a womanwith a profile
suggestive ofabetterprognosiswith reference to her cancer. Whether or not the risk
for recurrence is reduced by waiting to initiate ERT for 12 to 24 months after
definitive therapy is unclear-but such scheduling should further clarify a treatment
candidate's risk profile. The role of the progestogens in this setting cannot be
clarified from the current literature. There is no data that these agentswould reduce
the risk for recurrent disease, and their effect on lipids and lipoproteins must be
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considered seriously so as not to reduce the cardioprotective benefit afforded by
ERT.
BREAST CANCER
Endocrine Considerations in Breast Growth andDevelopment
The endocrine requirements for breast development and function are complex
with varied interactions among active and passive hormones [77]. Breast growth at
puberty is primarily dependent upon estrogen. The initial response in most young
girls to increasing levels of estrogen is an increase in size and pigmentation of the
areola and the formation of a subareolar mass ofbreast tissue. Estrogen is bound in
the breast in a manner similar to that in the uterus and vagina [78]. Prolactin is
required for the optimal development of estrogen receptors. In subprimate mam-
mals, estrogen replacement stimulates ductal growth, whereas progesterone is
necessary for adequate alveolar growth; however, full differentiation of the gland
requires insulin, cortisol, thyroxin, prolactin, and growth hormone [78]. Mammary
changes occur routinely in response to the estrogen-progesterone sequence of the
normal ovarian cycle.
The estrogen-induced impetus to mammary epithelial stem cell division requires
the presence of insulin. Final differentiation of the alveolar epithelial cell into a
mature milk cell is accomplished in the presence of prolactin, but only after prior
exposure to cortisol and insulin. Minimal quantities of thyroid hormone are neces-
sary to complete this development. As noted above, numerous hormones are
required for appropriate breast growth, but mild deficiencies in any of these can be
compensated forby excess prolactin.
Endocrine Considerations in Breast Cancer
Although the pathogenesis ofbreast cancer remains enigmatic, there is consider-
able evidence that endocrine factors play a critical role. The main indications for a
hormonal contribution to the etiology of breast cancer in humans comes from
epidemiologic studies showing a protective effect of early first pregnancy and early
castration, and the negative effect of early menarche, late menopause, and nullipar-
ity. It has also been postulated that normal estrogen stimulation and luteal inade-
quacy, characterized by diminished progesterone secretion, could explain the main
epidemiologic features of the etiology ofbreast cancer [79]. Unfortunately, a causal
relationship between hormones and breast cancer risk has been sought-but not
found [80,81]. Many of the epidemiologic findings did not persist in cross-culture or
single-culture studies, and population bias has been a persistent problem. Luteal
phase inadequacy has not been found in youngwomen at high genetic risk for breast
cancer or in pre-menopausal womenwithbreast cancer [82-84].
With advances in technology, numerous investigators have specifically attempted
to understand and quantify the role of estrogen further. The only significant report
on plasma estrogen levels in post-menopausal breast cancer was by England et al.
[85]. Twenty-five breast cancer patients and 25 controls were studied, and it was
found that estrogen levels were 30 percent higher in the former population. There
have been at least five case-control studies investigating urinary estrogens in post-
menopausalwomenwithbreast cancer [86-90]. These studies support the findingsof
increasing levels ofestrogen in thispatient population.
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Recent work by Siiteri et al. [91] and Moore et al. [92] emphasize the theoretical
importance of bioavailable estrogen fractions in the pathogenesis of breast cancer.
Siiteri et al. investigated a small group of breast cancer cases and controls matched
for age,weight, height, and menstrual status [91]. In bothgroups, theyfound that the
known association between obesity, reduced sex hormone bindingglobulin (SHBG),
and increased free estradiol (E2) held. More important, they found that some
"normal weight" breast cancer patients with normal SHBG levels had an elevated
percentage of free E2. These results, based on a small number of patients, suggest
that, in the breast cancer population, serum-free E2 may be elevated by factors
unrelated to SHBG concentration.
Moore et al., looking at 38 post-menopausal women with breast cancer and 38
controls of similar age and weight, compared total and non-protein bound E2 levels
[92]. Breast cancer cases had significant higherlevelsofE2 and non-protein bound E2
than controls as well as significantly less SHBG. Indeed, the level of non-protein
bound E2 among the cases was nearly four times that ofcontrols. Unfortunately, the
interpretation ofthese results is difficult due to the fact that cases and controls were
drawn from different populations.
The clinician attempting to treat post-menopausal women with estrogen is left
with a contradictory literature regarding breast cancer pathogenesis, with only a
modest potential for practical applications. The most useful information available
involves the effect of exogenous as well as endogenous estrogens on breast cancer
risk/recurrence. The following discussion summarizes current data which can be
utilized in the context ofmanagement strategy.
Pregnancy andBreast Cancer
During pregnancy, the diagnosis of breast cancer becomes difficult due to the
physiologic enlargement which tends to obscure the presence of new breast masses.
Moreover, patients and physicians often incorrectly identify a new mass in the breast
as a normal consequence ofpregnancy, therebydelayingtimelymedical intervention.
Mammographybecomes almost useless due to thechanges inbreastparenchyma. All
of these factors contribute to the observation that pregnant patients tend to present
with more advanced disease than non-pregnant patients with breast cancer [93,94].
Yet despite these seemingly deleterious factors, it was recognized over 50 years ago
that pregnant patients without histologic axillary node involvement have a favorable
prognosis and were responsive to conventional therapy [95]. More recent work
comparing pregnant patients with breast cancer to non-pregnant breast cancer
patients of similar age and stage has found that the additional factor of pregnancy
did not adversely affect prognosis [96-98]. The independent variable of youth-a
factor associatedwith more aggressive disease-now appears to explain the unfavor-
able prognosis in manypregnant breast cancerpatients [98].
Enough women have now become pregnant after treatment for breast cancer to
allow for a limited literature regarding recurrence of disease. Several authors have
noted that breast cancer patients who subsequently became pregnant have done
better than comparable non-pregnant patients [96,99,100]. Unfortunately, a selec-
tion bias was probably introduced in these investigations, as women with a poor
prognosis were generally counseled against subsequent pregnancy. In addition,
women with recurrent cancer were unlikely to become pregnant. Misleading conclu-
sions have also stemmed from the fact that women surviving long enough to become
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pregnantwere compared againstwomenwho succumbed to breast cancer early after
diagnosis. Fortunately, thismethodological flawhasbeen eliminated byusingcareful
case matching. Indeed, Cooper and Butterfield compared women with a history of
breast cancer who became pregnant to similar breast cancer patients who did not
become pregnant andfound asignificant prolongation in survival in the formergroup
[101].
Recommendations regarding pregnancy andbreast cancershouldbe guidedbythe
knowledge that recurrence is always possible. Wyle and DiSaia cautiously suggest
that pregnancy may offer a benefit similar to additive hormonal therapy (i.e.,
tamoxifen) in women with receptor-positive tumors [77]. Considerably more investi-
gative work, employing careful case matching, is required before management
strategies can be generalized.
Oral Contraceptives andBreast Cancer
Oral contraceptives have been used widely since the early 1960s. A substantial
body ofliterature currently exists on the relationship between oral contraceptive use
and theriskofbreast cancer. Numerous studies have failed toidentify anyincrease in
the incidence of breast cancer in this population [102-104]. Indeed, after an
extensive review of the subject, the Food and Drug Administration has concluded
that there is no increased risk ofbreast cancer in users oforal contraceptives [105].
In the context of considering estrogen use in high-risk populations, it becomes
important to consider the record oforal contraceptive use in such groups ofwomen.
As discussed by Henderson et al., breast tissue mitotic rate, which increases during
the luteal phase, is a significant determinant of a woman's breast cancer risk [106].
Theoretically, therefore, combination oral contraceptives, which stimulate the luteal
phase of the cycle, may under certain circumstances increase the risk of breast
cancer.
The "circumstances" ofgreatest significancewould be those inwhich thewoman's
average breast tissue mitotic activity on combination oral contraceptives exceeds her
"normal" activity. Specifically, late adolescence and the perimenopause have come
under scrutiny because both periods are hallmarked by anovulatory cycles-just the
right setting in which to identify an increased risk from the combination type ofpill.
Five studies have specifically reported on the use of combination oral contracep-
tives in the perimenopausal population [107-111]. Although the range of reported
relative riskswaswide, all ofthese studies found some evidence ofan elevated riskof
breast cancerwith such use. In the majority ofthese reports, the excess riskwas seen
in women age 46-60 [107-110]. In only one report was the excess risk observed in
women over 50 [111]. Unfortunately, none of these studies dealt with the possible
risk-modifying effect of specific oral contraceptive formulations. In fact, the signifi-
cance of different formulations of combination oral contraceptives on breast tissue
mitotic activity is not known. On a theoretical basis only, it can be presumed that
those preparations with higher dosages of both estrogen and progestogen will have
the greatest effect.
The other key period of consideration is late adolescence. Pike et al. recently
found that long-term oral contraceptive use during this time carried with it a
substantial increase in breast cancer risk [112]. Even more recent data, however,
suggested that the greatest risk is imparted with oral contraceptive use before first
full-term pregnancy [113].
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MenopausalEstrogens andBreast Cancer
Although the risk of endometrial cancer associated with ERT is well established,
the relationship between menopausal estrogen use and breast canceris far less clear.
Numerous studies have attempted to evaluate this issue and, overall, have failed to
demonstrate any significant increase in breast cancerwith ERT [114-140]. Unfortu-
nately, the vast majority of these reports have dealt with small numbers of women,
thereby limiting their statistical power to detect a difference between users and
non-users ofmenopausal estrogen preparations.
Two recent studies have attempted to overcome this methodological issue and
clarifyconflicting epidemiologic observationsbycombiningdata from several reports
using meta-analysis [141,142]. The latter is a systematic, quantitative means of
combining data across studies to increase statistical power and to generalize results
[143].
Dupont and Page, in their review, subdivided the literature based on type of
endogenous estrogen prescribed, duration of use, and dosage [141]. They found a
limited amount of data comparing types of menopausal estrogen. There is some
suggestion, however, that estradiol products maybe associatedwith an increased risk
of breast cancer [125,131,144]. This risk was noted with estradiol valerate [144] and
injectable estradiol [125] and therefore has little clinical applicability for most U.S.
practitioners.
Dupont and Page found that several authors noted a modest, but persistent and
statistically significant, trend ofincreasing riskwith increasing duration oftreatment
[122,132,144]. Other authors, however, have failed to demonstrate any evidence of a
positive duration-risk relationship [119,120,129,131-133,135,136,138], or they have
found that breast cancer risk fluctuates inconsistently with increasing duration of
treatment [125,140]. Key and Pike [145], noting that several negative studies em-
ployed hospital control groups, suggested that these reports may be affected by
unknown biases. Two large, well-controlled studies have used population-based
control groups, however, and failed to find an increased risk of breast cancer with
increasingduration ofestrogen use [135,136]. Inthemeta-analysisofSteinburg et al.,
breast cancer relative risk was increased to an estimated 1.3 (CI, 1.2-1.6) after 15
years of estrogen use [142]. These reviewers did not find an increased risk with five
years or less of ERT. No report to date has been able to separate clearly the critical
issue of latency of effect of menopausal estrogen use from the effect of duration of
use. Thus, the current literature does not permit a definite conclusion to be made
regarding the presence or absence of a positive duration-risk relationship. The
contradictory results may be due, in part, to differences in dosages and types of
treatment found among the studies.
In terms of the relationship between daily dosages of estrogen and breast cancer
risk, the only worthwhile literature available concerns conjugated equine estrogen
preparations [115,120-122,129,131,134,136,144]. Dupont and Page found that the
combined relative risk for women who took 0.625 mg per day or less was 1.08 (CI,
0.96-1.2) [141]. Indeed, the results of all the relevant studies were mutually consis-
tent [115,120-122,129,131,134,136,144]. The combined relative risk for women using
1.25 mg per day was also low. The individual relative risks from the latter studies
differed significantly from each other, however, indicating that factors other than
high-dose conjugated equine estrogen may affect cancer risk in some ofthese reports
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[141]. Although none of the estimated relative risks exceeded 2.0, the current
literature does not permit confident conclusions regarding this treatment dose.
There are several other important issues which are worthy ofnote when consider-
ing menopausal estrogen use and breast cancer. In all instances discussed, however,
the reader should remember that any conclusions based on the current literature
reflect a myriad ofpatients, estrogen preparations, and treatment schedules.
Several studies have looked at breast cancer risks associated with ERT among
women with histologic evidence ofbenign breast disease [121,134,136,138,139]. Four
of these five studies found relative risks which did not differ significantly from 1.0
[134,136,138,139]. The study by Ross et al. [121] found an increased risk-but was
based on only 14 women with breast cancer who had taken conjugated equine
estrogens and also had a history of benign breast disease. Dupont and Page found
that the combined relative risk of breast cancer from these studies was 1.16 (CI,
0.89-1.5). Moreover, the relative risks ofthe individual studies, overall, did not differ
significantly from each other. Therefore, this meta-analysis provided considerable
evidence that the elevation in breast cancer risk among women with benign breast
disease isnotgreaterthan50percent. Asconcluded byDupont and Page, ahistoryof
benign breast disease does not constitute grounds for denyingwomen ERT [141].
Steinburg et al. found in their meta-analysis that the effect of ERT on breast
cancer risk was enhanced among women with a family history ofbreast cancer (RR
risk, 3.4; CI, 2.0-6.0) [129,132,134,147]. This finding is a critical pointwhich requires
further clarification, although, based,on the current literature, these candidates for
ERT should be considered high-risk for long-term therapy (greater than 15 years).
Colditz et al. recently reported on data collected from the Nurses' Health Study
[150]. Female registered nurses were followed prospectively for ten years, thereby
greatly reducing the potential for bias. Past use ofestrogens, regardless of duration,
was not associatedwith anincreased risk ofbreast cancer; however, riskwas elevated
among current users (RR, 1.36; CI, 1.1-1.7). Of interest is the observation that
current users ofERTwho did not consume alcohol did not have an increased risk of
breast cancer (RR, 0.99; CI, 0.62-1.60). Whether or not this finding is due to chance
or a true interaction remains tobe clarified. There is no strongevidence, todate, that
estrogen users should be counselled against alcohol consumption.
It has been suggested that progestogen use with ERTwill reduce the risk ofbreast
cancer [127]. As eloquently discussed by Ernster and Cummings [148], there is no
substantial evidence to support this treatment approach. Based on only ten patients,
Bergkvist et al. suggested that progestogen use may increase cancer risk [144]. On a
practical level, it is useful to remember that breast cell division is predominantly in
the latter part of the menstrual cycle, when progesterone levels are high [149].
Therefore, not only is there no theoretical reason tobelieve thatprogestogens should
decrease breast cancer risk, but the potential for negatively affecting lipids and
lipoproteins and reducing the cardioprotection afforded by estrogen should take
precedence.
Based on the current and admittedly inconsistent literature, it appears unlikely
that ERT significantly increases breast cancer risk in the majority ofhealthywomen.
Issues such as dosage and duration of treatment need to be considered cautiously.
Minimal dosages to relieve symptoms and prevent long-term sequelae should be
utilized. Duration of treatment must be weighed against the more prevalent conse-
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quences of estrogen deficiency such as hip fracture and, most important, CHD.
Treatment strategies for women with a family history of breast cancer should be
individualized. There is no evidence that short-term therapy for symptom relief
poses a significant risk to this latter population.
ERTandBreast CancerRecurrence
When faced with the dilemma ofconsidering menopausal estrogen use for women
with a history ofbreast cancer, there is no data upon which to base clinical strategy.
On a purely theoretical basis, the available literature on breast cancer recurrence
after pregnancy may offer some evidence that menopausal estrogens pose no risk to
women whose cancer has a positive prognostic profile. Here the argument could be
made that typical estrogen schedules "mimic" the early follicular phase milieu, with
reference to estrogen levels, and should be considered "safer" than the endocrine
environment of pregnancy. The clinical decision to act upon such theory must be
individualized.
There exists a very modest literature suggesting that survival after the diagnosis of
breast cancer is improved in the setting of prior non-contraceptive estrogen use
[151-153]. Bergkvist et al. found that relative survival rate was significantly higher in
patients who had received ERT. The most favorable course occurred in women, 50
years old or more, who were recent users, and corresponded to a 40 percent
reduction in excess mortality [151]. Although these authors entertain the notion that
their findings might be explained by direct biologic effects of estrogen on tumor
characteristics, the effect of a number of confounding variables (i.e., selection bias:
healthier women are given ERT) is undoubtedly significant in this setting. Indeed,
this type ofreport does little to assist the clinician in decision making.
Conclusion
The complexities surrounding breast disease and menopausal estrogen use need to
be separated, once and for all, from clinical experience with the endometrium and
ERT. The established management strategy with reference to preventing the emer-
gence of endometrial carcinoma in the setting of ERT-the judicious use of
progestogens-has no corollary when considering breast cancer risk in the meno-
pausal population. The literature on the latter topic, however, suggests that the
risk:benefit ratio for most healthy women favors estrogen use. There are no guide-
lines for the womanwith a history ofbreast cancer. Ifthere is a candidate for ERT in
this population, she is clearly the woman whose cancer has a better prognostic
profile, i.e., negative axillary nodes, positive estrogen receptor status, at least five
years' survival after definitive cancer therapy. Clinicians should be prepared to deal
with alternative treatment modalities to help with symptom reliefand alleviate other
known risks for osteoporosis and CHD.
SUMMARY
Treatment strategies for the woman with a history ofendometrial or breast cancer
experiencing menopausal symptoms, or interested in preventing the long-term
consequences of estrogen deficiency, remain a controversial area in health care.
There are no established guidelines. One plausible cornerstone of management is
choosing the "right" candidate for treatment-the woman with a profile suggestive
of a better prognosiswith reference to her cancer.
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While the definitive, methodologically sound study has not been conducted
involving either endometrial cancer or breast cancer patients, there does exist a
modest literature regarding the former. These reports suggest that ERT does not
increase the risk for endometrial cancer recurrence; however, critical controversies
such as when to start after cancer treatment, what estrogen vehicle to use, and the
role ofprogestins remain to be clarified.
There are no reports inthe English literature on the use ofERT and breast cancer
recurrence. Inferential supportfortheuse ofpost-menopausal estrogens comesfrom
generally poorly designed studies showing that breast cancer recurrence does not
increase after pregnancy. It has been argued that the estrogen exposure with
post-menopausal preparations should be far less "worrisome" than that found in the
pregnant state. There is no clinical applicability to this postulate, and management
needs tobe individualized. It is imperative thatwomenwith a historyofbreast cancer
be fully appraised ofalternative treatment modalities.
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